STUDY OF SERUM PCSK9 LEVELS IN CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING HAEMODIALYSIS.

Abstract

Introduction: Chronic Kidney Disease is defined as presence of kidney damage or an
estimated glomerular filtration rate (eGFR) less than 60ml/min/1.73mt2 persisting for 3 months
or more. PCSK-9 (Proprotein convertase subtilisin/kexin type 9) is a new biomarker which has
been observed to be raised in CKD patients.
Aims: To compare serum PCSK9 levels in patients suffering from chronic kidney disease and
normal individuals and to observe the effect of haemodialysis on the levels among patients.
Materials and methods: The study was conducted from 1st June 2018 to 31st February 2019.
60 patients suffering from CKD in between 16 years to 65 years of age of both genders were
consecutively enrolled (Study Group). 60 normal age matched and gender matched controls
were also included in study for comparison (Control Group). Serum PCSK9 was estimated
using Ultra-Sensitive Human PCSK9 ELISA EK1147 PicoKineTM (BOSTER). Its levels were
again estimated in study group after haemodialysis. Findings were compared using appropriate
statistical instruments.
Observation: Serum PCSK9 levels were significantly higher in study
group(1983.001243.17ng/ml) as compared to control group (23.488.71ng/ml). There was
significant reductional effect of haemodialysis on serum PCSK9 levels ( Pre-dialysis value
1983.00±1243.17ng/ml and post-dialyses value 1889.88±1237.64 ng/ml.).
Conclusion: PCSK9 is a new biochemical diagnostic tool, which is elevated when person has
chronic kidney disease but levels fall down when haemodialysis is performed.